Autolus Therapeutics plc
AUTLNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $409.88M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.18$2.58
- Volume (live)
- -
- Avg. volume (3M)
- 1.65M
Autolus Therapeutics (AUTL) Stock Price & Financial Analysis
Autolus Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.50 - $1.58 |
|---|---|
| 52-Week High | $2.58 |
| 52-Week Low | $1.18 |
| Open | $1.58 |
| Volume (last close) | 1.52M |
| Average Volume (3M) | 1.65M |
| Revenue (TTM) | 117.35M |
|---|---|
| Net Income (TTM) | -280.03M |
| Free Cash Flow (TTM) | -257.38M |
| EPS (TTM) | −$1.05 |
| Profit Margin | -238.62% |
| Operating Margin | -210.76% |
| Return on Equity (ROE) | -374.17% |
| Debt to Equity | 1.12 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 409.88M |
|---|---|
| Shares Outstanding | 266.16M |
| Price to Sales (P/S) | 3.49 |
| Price to Book (P/B) | 5.48 |
| EV/EBITDA | -1.47 |
| 50-Day MA | $2.02 |
|---|---|
| 200-Day MA | $1.67 |
| 1-Year Change | +5.33% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Autolus Therapeutics at a Glance
As of the Oct 23, 2026 close, Autolus Therapeutics (AUTL) has a market capitalization of $409.88M. The stock trades at 3.5× sales. Over the trailing twelve months it lost $280.03M on revenue of $117.35M and burned $257.38M of free cash flow. Revenue grew 292.1% year over year.
As of its latest reported balance sheet, it holds $171.41M in cash and securities against $83.51M of debt, a net cash position of $87.90M.
Autolus Therapeutics does not currently pay a dividend.
The share price is up 5.3% over the past year. At $1.54 (the Oct 23, 2026 close) it sits within its 52-week range of $1.18 to $2.58, below its 200-day moving average of $1.67.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $7.70, 400.0% above the Oct 23, 2026 close.
Frequently Asked Questions About Autolus Therapeutics
What is the current stock price for AUTL?
As of the Oct 23, 2026 close, AUTL stock trades at $1.54. The 52-week range is $1.18–$2.58, with a day range of $1.50–$1.58.
What is the P/E ratio for AUTL?
The P/E ratio (Price-to-Earnings) for AUTL is shown in the Key Statistics section. This valuation metric helps compare Autolus Therapeutics plc to industry peers.
Does AUTL pay dividends?
Autolus Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for AUTL?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for AUTL is Buy. The average 12-month price target is $7.70, a 400.0% upside from the Oct 23, 2026 close of $1.54.
What is the market cap of AUTL?
As of the Oct 23, 2026 close, Autolus Therapeutics's market capitalization is $409.9M, classifying it as a small-cap company. Autolus Therapeutics operates in the Healthcare sector within the Biotechnology industry.